Development and preliminary evaluation of a multivariate index assay for ovarian cancer (Q30858808)

18 August 2017

Development and preliminary evaluation of a multivariate index assay for ovarian cancer (English)

1 reference

18 August 2017

1 reference

multivariate statistics

1 reference

Brian C Mansfield

8

0 references

author name string

Suraj D Amonkar

1

1 reference

18 August 2017

Greg P Bertenshaw

2

1 reference

18 August 2017

Tzong-Hao Chen

3

1 reference

18 August 2017

Katharine J Bergstrom

4

1 reference

18 August 2017

Jinghua Zhao

5

1 reference

18 August 2017

Partha Seshaiah

6

1 reference

18 August 2017

Ping Yip

7

1 reference

18 August 2017

language of work or name

English

0 references

publication date

25 February 2009

1 reference

18 August 2017

1 reference

18 August 2017

4

1 reference

18 August 2017

2

1 reference

18 August 2017

e4599

1 reference

Creative Commons Attribution 4.0 International

18 August 2017

start time

25 February 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Combining a symptoms index with CA 125 to improve detection of ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643010

Systematic evaluation of candidate blood markers for detecting ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643010

A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643010

Management of adnexal mass

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643010

Development of an ovarian cancer symptom index: possibilities for earlier detection.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643010

Surveillance of women at high risk for hereditary ovarian cancer is inefficient

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643010

Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643010

Validation of referral guidelines for women with pelvic masses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643010

Use of proteomic patterns in serum to identify ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643010

Two-sided confidence intervals for the single proportion: comparison of seven methods

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643010

Misstaging of ovarian cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2643010

Predictors of comprehensive surgical treatment in patients with ovarian cancer.

21 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0004599

Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0004599

Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0004599

Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0004599

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0004599

Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer

21 January 2018

1 reference

12 December 2020

Role of cancer antigen-125 from pleural & ascitic fluid samples in non malignant conditions

1 reference

12 December 2020

C-reactive protein concentrations and subsequent ovarian cancer risk

1 reference

12 December 2020

Diagnostic markers for early detection of ovarian cancer

1 reference

12 December 2020

Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer

1 reference

12 December 2020

Benign conditions associated with raised serum CA-125 concentration

1 reference

12 December 2020

Cancer antigen 125 associated with multiple benign and malignant pathologies

1 reference

12 December 2020

Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas

1 reference

12 December 2020

Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence

1 reference

12 December 2020

Preoperative evaluation of CA 125 and CA 19-9 serum levels in patients with ovarian masses

1 reference

12 December 2020

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

1 reference

12 December 2020

Random Forests

1 reference

Astrophysics Data System

15 December 2022

https://ui.adsabs.harvard.edu/abs/2001MachL..45....5B/citations

Identifiers

DOI

10.1371/JOURNAL.PONE.0004599

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yc7mjlyr65g5rhvy7qgjpbyb6e

30 July 2022

release_yc7mjlyr65g5rhvy7qgjpbyb6e

ADS bibcode

2009PLoSO...4.4599A

0 references

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yc7mjlyr65g5rhvy7qgjpbyb6e

30 July 2022

https://api.fatcat.wiki/v0/release/yc7mjlyr65g5rhvy7qgjpbyb6e

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/yc7mjlyr65g5rhvy7qgjpbyb6e

1 reference

30 July 2022